Director, President and Head of R&D · Taysha Gene Therapies, Inc. · Common Stock
Side
SELL
Value
$124K
Shares
26.9K
Price
$4.61
Executed
Jan 26, 2026
Disclosed
Jan 27, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Jan 26 executedJan 27, 2026 disclosed
TSHA · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+4 / 15
2 prior trades recorded in this security
Frequency & clustering+5 / 15
1 other actor traded the same direction within 14 days
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Nagendran Sukumar filed this Form 4 reporting a open-market sale of TSHA on Jan 26, 2026. It became public on Jan 27, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director, President and Head of R&D
Nagendran Sukumarcik:0001665124
Issuer
Taysha Gene Therapies, Inc.cik:0001806310
Revision history · 0
No field has changed since this record was first ingested.
